Advancing Cardiovascular Treatment
Our Capabilities
Pharsight is the largest drug development modeling and simulation company in the world. Having completed more than 100 projects in 2005 alone, Pharsight Strategic Consulting Services provides expert scientific capabilities to address critical development questions from preclinical testing to post-launch market surveillance. Pharsight resources include seasoned practitioners from industry, government, academia, and consulting. Our multidisciplinary team of more than 20 Ph.D. and MD scientists can optimize your drug development decisions through quantitative exploration of development knowledge and uncertainty that integrates drug/disease models, trial models, and predictive market models.
Leaders in Cardiovascular Drug Development Consulting
Pharsight has supported more than 20 cardiovascular drug programs for industry clients over the past eight years, spanning all phases of clinical development.
Our consultants have addressed key issues in trial design, dose selection and development strategy for a broad range of cardiovscular diseases and conditions, including congestive heart failure (CHF), hypertension, deep vein thrombosis (DVT), and hyperlipidemia. Our compilations of public data from the clinical and scientific literature in several cardiovascular indications provide a ready context for model-based meta analysis to assess your compound's performance against competing therapies.
Our leading-edge approaches to quantitative decision making are featured in recent presentations at scientific conferences and in peer-reviewed journals.